CTLA4 and melanoma: While phase I/II clinical trials in melanoma patients testing DNMTi’s in combination with anti-CTLA-4 or anti-PD-1 mAbs are still ongoing (71), a phase II trial in acute myeloid leukemia reported on the combination of the DNMTi Azacitidine and PD-1 inhibitor Nivolumab.